U.S. markets closed
  • S&P Futures

    3,409.25
    -23.25 (-0.68%)
     
  • Dow Futures

    27,950.00
    -184.00 (-0.65%)
     
  • Nasdaq Futures

    11,617.75
    -73.50 (-0.63%)
     
  • Russell 2000 Futures

    1,592.30
    -10.80 (-0.67%)
     
  • Crude Oil

    39.80
    -0.23 (-0.57%)
     
  • Gold

    1,917.00
    -12.50 (-0.65%)
     
  • Silver

    24.88
    -0.37 (-1.45%)
     
  • EUR/USD

    1.1846
    -0.0021 (-0.18%)
     
  • 10-Yr Bond

    0.8160
    +0.0190 (+2.38%)
     
  • Vix

    28.65
    -0.70 (-2.39%)
     
  • GBP/USD

    1.3127
    -0.0017 (-0.13%)
     
  • USD/JPY

    104.7350
    +0.1750 (+0.17%)
     
  • BTC-USD

    12,777.58
    +1,720.58 (+15.56%)
     
  • CMC Crypto 200

    256.11
    +11.22 (+4.58%)
     
  • FTSE 100

    5,776.50
    -112.72 (-1.91%)
     
  • Nikkei 225

    23,454.85
    -184.61 (-0.78%)
     

How Much Of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Do Institutions Own?

Simply Wall St
·5 mins read

Every investor in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. We also tend to see lower insider ownership in companies that were previously publicly owned.

Corbus Pharmaceuticals Holdings is not a large company by global standards. It has a market capitalization of US$147m, which means it wouldn't have the attention of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about Corbus Pharmaceuticals Holdings.

View our latest analysis for Corbus Pharmaceuticals Holdings

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Corbus Pharmaceuticals Holdings?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that Corbus Pharmaceuticals Holdings does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Corbus Pharmaceuticals Holdings' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Corbus Pharmaceuticals Holdings is not owned by hedge funds. The company's largest shareholder is BlackRock, Inc., with ownership of 7.7%. Meanwhile, the second and third largest shareholders, hold 6.2% and 4.6%, of the shares outstanding, respectively.

Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 19 shareholders, meaning that no single shareholder has a majority interest in the ownership.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Corbus Pharmaceuticals Holdings

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own some shares in Corbus Pharmaceuticals Holdings, Inc.. In their own names, insiders own US$6.4m worth of stock in the US$147m company. This shows at least some alignment, but I usually like to see larger insider holdings. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public holds a 39% stake in Corbus Pharmaceuticals Holdings. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

With a stake of 6.2%, private equity firms could influence the Corbus Pharmaceuticals Holdings board. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For example, we've discovered 4 warning signs for Corbus Pharmaceuticals Holdings (1 is concerning!) that you should be aware of before investing here.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.